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Abstract
Background: Protein biomarker studies are currently hampered by a lack of measurement standards to
demonstrate quality, reliability and comparability across multiple assay platforms. This is especially pertinent for
immunoassays where multiple formats for detecting target analytes are commonly used.
Findings: In this pilot study a generic panel of six non-human protein standards (50 - 10^7 pg/mL) of varying
abundance was prepared as a quality control (QC) material. Simulated “normal” and “diseased” panels of proteins
were prepared in pooled human plasma and incorporated into immunoassays using the Meso Scale Discovery
®
(MSD
®) platform to illustrate reliable detection of the component proteins. The protein panel was also evaluated as
a spike-in material for a model immunoassay involving detection of ovarian cancer biomarkers within individual
human plasma samples. Our selected platform could discriminate between two panels of the proteins exhibiting
small differences in abundance. Across distinct experiments, all component proteins exhibited reproducible signal
outputs in pooled human plasma. When individual donor samples were used, half the proteins produced signals
independent of matrix effects. These proteins may serve as a generic indicator of platform reliability.
Each of the remaining proteins exhibit differential signals across the distinct samples, indicative of sample matrix
effects, with the three proteins following the same trend. This subset of proteins may be useful for characterising
the degree of matrix effects associated with the sample which may impact on the reliability of quantifying target
diagnostic biomarkers.
Conclusions: We have demonstrated the potential utility of this panel of standards to act as a generic QC tool for
evaluating the reproducibility of the platform for protein biomarker detection independent of serum matrix effects.
Introduction
Protein biomarkers for diagnosis of disease have formed
the basis of clinical research proteomics for several dec-
ades [1-3]. In spite of FDA approval of various disease
protein biomarkers, including CA-125 for ovarian cancer
and prostate specific antigen for prostate cancer, few
biomarkers are adopted in standard clinical practices
[4]. The FDA highlighted this issue as a major challenge
to developing new medicinal products [5]. A key hin-
drance identified was the lack of assay robustness, which
may be improved using appropriate measurement stan-
dards and control materials. These reference standards
ensure robust comparability of a diagnostic test for the
same patient between distinct test sites, or for tests after
significant time intervals.
Many protein-based detection methods suffer from a
lack of standardisation with the reagents and methods
employed [6], in a similar way to microarray assays
prior to the advent of the MIAME checklist [7]. With
conventional immunoassays, significant variability may
exist by using finite sources of polyclonal antibodies
which differ in immunogenicity [8]. Variable perfor-
mance from distinct platforms may arise from differ-
ences in reagent quality or platform bias. Commercial
immunoassay kits lack standardisation to ensure the tra-
ceability of measurements. Often the source or identity
(e.g. clone number for monoclonal antibodies) of cap-
ture and detection antibodies used in kits are not stipu-
lated [9]. Improved standardisation may be achieved * Correspondence: susan.pang@lgcgroup.com
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strating the reproducibility of the platform function.
Such generic standards are emerging for mass spectro-
metry analysis of proteins, though they are specific to
this platform rather than for broad stream applications
including immunoassays [10].
For most protein biomarker assays, the diagnosis of
diseases may be achieved by detecting the appropriate
protein biomarker(s) above specified thresholds, along-
side the generic QC proteins to indicate platform func-
tionality. The change in the collective signal output
profile of these QC proteins may indicate the presence
of inhibitors within the biological matrix, and may infer
that the robustness of detection of the target diagnostic
biomarker(s) is also adversely affected.
In this paper we have prepared a panel of generic
protein standards and evaluated its utility as a quality
control (QC) material using the to MSD
® platform.
The scope of detecting each protein amidst the full
panel of proteins was assessed, as well as the ability to
identify small known changes in the protein composi-
tion. The panel of protein standards was also evaluated
as a spike-in material, by supplementing individual
donor plasma (ovarian cancer diseased and non-dis-
eased) samples with the QC material. This pilot study
revealed the value of the QC material as an indicator
of platform robustness, as well as for highlighting any
matrix effects associated with individual samples that
may influence the reliability of detecting the target
analytes within the test samples.
Experimental sections
Preparation and storage of the generic panels of protein
standards
A generic panel of protein standards was prepared for
use as a quality control (QC) material. The composition
of this generic panel of proteins (incorporating mouse
CCL6 [Uniprot: P27784], mouse lungkine [Uniprot:
Q9WVL7], chicken caronte [Uniprot: Q9PUK2], mouse
soggy [Uniprot: Q9QZL9], firefly luciferase [Uniprot:
Q27758] and chicken egg lysozyme [Uniprot: P00698])
is shown in Table 1. Six non-human proteins that vary
in their chemiphysical properties, i.e. size, charge, hydro-
phobicity and isoelectric points were selected. Sequence
comparisons were made between these non-human pro-
teins and their human homologues to confirm sufficient
differences in the peptide sequences exist, or in the case
of soggy, that there is no endogenous presence of pro-
tein in adult human serological samples. These criteria
ensure that the proteins are amenable for use as spike
material within human serological samples. For the
assays, the antibodies raised against each protein were
selected on the basis of their specificity to the species of
the chosen proteins.
Biological test samples were spiked with the QC mate-
rial, extending over a broad dynamic range (50 - 10
7 pg/
mL) emulating the natural abundance of proteins in ser-
ological samples [11]. If any of these component pro-
teins provide a robust signal independent of biological
matrix effects, they may be indicative of a platform
being fit-for-purpose, as well as allowing assay perfor-
mance comparisons between different platforms. Addi-
tionally, if a subset of the spike proteins is influenced by
matrix effects associated with individual serological sam-
ples, this may bring into question the reliability of the
detection of the target analytes, which may also be
adversely affected by differential matrix effects.
Recombinant (mouse CCL6, mouse lungkine, chicken
caronte/Fc chimera, mouse soggy from R&D Systems,
Abingdon, UK) and purified proteins (firefly luciferase
and chicken egg lysozyme from Sigma, Poole, UK) were
reconstituted in PBS prior to gravimetric preparation of
the 10× stock QC material (also termed the normal
panel of generic standards) and stored at - 80°C. Refer
to Additional file 1 for details of characterisation of the
homogeneity, Additional file 2 for short-term stability
data and Additional file 3 for long-term stability of the
QC material.
Table 1 The components and parameters of the proteins within the spike panels
Non-human Protein
(with UniProt accession number)
Molecular
Weight
(kDa)
pI Purity
(%)
Spike concentration (pg/mL)
Normal panel of generic standards “Simulated diseased” panel of standards
Mouse_CCL6 P27784 10.7 9.38 > 97 50 100
Mouse_Lungkine
Q9WVL7
16.5 7.07 > 90 10
3 10
3
Chicken_Caronte Q9PUK2 56 6.37 > 90 10
4 10
4
Mouse_Soggy Q9QZL9 26.8 7.18 > 90 10
5 3×1 0
5
Firefly_Luciferase Q27758 120 6.72 10-35 10
6 6.67 × 10
5
Chicken-Egg-White_Lysozyme P00698 14.7 9.36 ≥ 90 10
7 10
7
The “normal” panel of generic standards was used for all work, whereas the “simulated diseased” panel of protein standards was incorporated only in the study
to evaluate the ability to identify known changes in composition of the generic standards
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Direct MSD
®-based assays were constructed for each of
the six spike proteins and four candidate ovarian cancer
biomarkers, either alone or within serological samples.
Capture antibodies (rat anti-CCL-6, rat anti-lungkine,
rat anti-soggy, rat anti-epidermal growth factor receptor
(EGFR), mouse anti-osteopontin, and mouse anti-inter-
leukin-8 (IL-8) monoclonal antibodies (mAbs) and goat
anti-caronte polyclonal antibody (pAb) (R&D Systems);
anti-luciferase and anti-CA-125 mouse mAbs (AbCam,
Cambridge, UK) and mouse anti-lysozyme mAb (Cosmo
Bio, Tokyo, Japan) diluted in PBS (at 1-8 μg/mL anti-
body), were added to wells on either MULTI-ARRAY™
standard bind or high bind MSD
® plates (Meso Scale
Discovery
®, Gaithersburg, USA) and incubated over-
night at 4°C. The plate was decanted and each well
incubated with 150 μL blocking buffer (phosphate-buf-
fered saline (PBS), pH 7.4; 1% (w/v) BSA, 0.05% (w/v)
sodium azide) on a shaker for 1 hour at room tempera-
ture. After three washes with PBS, 0.05% (w/v) polyox-
yethylenesorbitan monolaurate (Tween20), 25 μLo f
samples and standards (six spike proteins, and human
recombinant EFGR/Fc chimera, IL-8, and osteopontin
(R&D Systems)) diluted in either blocking buffer, pooled
normal human plasma (Firefly Scientific Limited, Man-
chester, UK), or single donor normal and ovarian cancer
diseased plasma (Sera Laboratories International, Hay-
wards Heath, UK) were added to each well and incu-
bated for 1 hour at room temperature on the shaker.
After three washes, 25 μL MSD
® SULFO-TAG detection
antibody (1 or 2 μg/mL; prepared using the manufac-
turer’s protocol) was added to each well and incubated
for 1 hour at room temperature on a shaker.
The unreacted SULFO-TAG N-hydroxysuccinimide
(NHS)-ester has molecular weight of 1141 Daltons, and
after the labelling reaction, the conjugated SULFO-TAG
adds 1027 Daltons to the protein. As the SULFO-TAG
is a small hydrophilic molecule (approximately 1 kDa),
it is not expected to affect the function of large protein
conjugation partners such as antibodies, especially as
the SULFO-TAG is much smaller than biotin (13 kDa).
Biotin NHS-ester is the most commonly used method to
label antibodies, which also binds to the antibody via
primary amines in the same manner as the SULFO-
TAG NHS-ester and is generally not anticipated to
interfere with the binding of the antibody to the cognate
target antigen.
For labelling, lyophilised antibodies were directly
reconstituted in PBS, pH 7.9. For antibodies sourced in
solution, buffer exchange was performed with PBS, pH
7.9 using Zeba Desalt Spin columns with a 7000 Dalton
molecular weight cut-off threshold (Thermo Scientific).
The concentration of the antibody was then determined
b yt h eB C Ap r o t e i na s s a y( T h e r m oS c i e n t i f i c ,
Massachusetts, USA) using the microplate procedure. 3
nmol/μLS u l f o - T a gN H S - E s t e rt a g( M e s oS c a l eD i s c o v -
ery) was added to the antibody for the labelling step
using a molar challenge ratio of 12:1, and the sample
was mixed for 2 hours in the dark at room temperature.
The antibodies were then buffer exchanged into PBS,
pH 7.4/0.05% sodium azide using Zeba Desalt Spin col-
umns. The concentration of the labelled antibody was
then determined by BCA protein assay using the micro-
plate procedure. Absorbance of protein conjugate at 455
nm was measured by NanoDrop (Thermo Scientific) to
establish labelling ratio of Sulfo-tag to antibody. The
detection antibodies subjected to labelling were goat
pAbs: anti-luciferase (Promega, Southampton, UK), anti-
caronte, anti-CCL-6, anti-lungkine, anti-soggy, anti-
osteopontin, anti-IL-8 and anti-EGFR (R&D Systems).
Rabbit detection pAbs were anti-lysozyme (Millipore,
Watford, UK), and anti-CA-125 (Bioquote Limited,
York, UK). Wells were washed before addition of 150
μL of MSD
® Read Buffer T (with surfactant).
A voltage was applied to the carbon electrodes inte-
grated in the plate, initiating a redox reaction involving
ruthenium chemistry, resulting in the emission of light
detected by the cooled charge coupled device (CCD)
camera. The raw data output was analysed by MSD
®
Discovery Workbench 3.0 software.
Evaluating the detection of each analyte within the
protein mixture
Each of the spike mixtures with five proteins was pre-
pared in pooled normal human plasma, maintaining the
designated concentrations for each analyte as outlined
in Table 1 for the full complement of proteins. The six
combinations of five spike proteins were assayed along-
side the full panel of six spike proteins in pooled plasma
and the diluent (pooled normal human plasma) as the
negative control for each of the six uniplexed assays.
Three separate experiments were performed to evaluate
the scope of detecting each analyte amidst the complete
protein mixture. Triplicate determinants were incorpo-
rated within each experiment, and the data for each
separate experiment was shown.
Evaluating the ability to discriminate between two panels
with variable abundance in spike proteins within pooled
normal human plasma
Two distinct panels of the six protein spikes were pre-
pared, with the composition outlined in Table 1. One
panel was termed as the “normal” panel of generic stan-
dards. A second panel comprising of 1.5-3 fold changes
in the composition of three component proteins (CCL6,
soggy and luciferase) with all concentrations remaining
within the linear working range of the assay was desig-
nated as the “simulated diseased” panel of proteins.
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formed with both panels of protein standards, incorpor-
ating triplicate determinants for all three separate
experiments. The reliability of detecting known fold
changes in concentrations of selected spike proteins
diluted in pooled normal human plasma as the biologi-
cal matrix, was evaluated by comparing the fold changes
between the two protein panels. 7-point internal calibra-
tion curves were incorporated for the assay of each
analyte.
Ovarian cancer model spike-in study
Single donor plasma samples (six normal and six ovar-
ian cancer diseased) were supplemented with the QC
material to incorporate a 1× working concentration of
the six spike proteins and assayed for the six spike pro-
teins and four putative ovarian cancer biomarkers, CA-
125, EGFR, IL-8 and osteopontin. Experiments were
performed with internal calibration curves (except for
CA-125, as the recombinant protein could not be
sourced) with triplicate determinants, in a randomised
plate format for three separate experiments.
Data analysis
The MSD Discovery Workbench analysis software ver-
sion 3.0 was applied to process the data. A 4-parameter
logistic model was used for curve-fitting. PCA was per-
formed using SIMCA-P (Umetrics). Linear mixed-effects
models were fitted by residual (or restricted) maximum
likelihood using the program “R”.
Results
Evaluating the scope to detect each component protein
within the mixture
Each assay was initially constructed using a background
of buffer (blocking buffer) and then pooled normal
human plasma as the sample diluent for each analyte,
with the criteria that each analyte concentration used is
within the linear working range of the assays (data not
shown). The contribution to the signal output by each
cognate analyte amidst the full panel of proteins was
evaluated, to show that the presence of the five non-
cognate proteins have no adverse effect on each assay.
Each protein individually was removed from the mixture
to gauge the contribution by the protein to the overall
signal output (Figure 1). A reduction in signal output
was anticipated and observed for all assays upon omis-
sion of the cognate protein.
Evaluation of the robustness in detecting each
component protein within the spike material comprising
of six proteins in pooled normal human plasma
Two distinct panels of protein standards were prepared
with the same component proteins but differing
(known) concentrations for three proteins; CCL6, soggy
and luciferase. The ratios of these three analytes
between the two protein panels were experimentally
derived from three separate experiments by mean signal
outputs and interpolated concentrations from internal
calibration curves (Table 2) with the associated standard
error of the estimate shown for each analyte within each
experiment (Additional file 4). Analysis of data in terms
of the signal outputs rather than interpolated values
from internal calibration curves produced experimental
ratios closest to the theoretical ratios for five out of the
six assays. The only exception was the CCL6 dataset;
the ratio derived from the interpolated CCL6 concentra-
tions within the two panels more closely resembled the
theoretical ratio. This anomalous result with the CCL6
assay was due to the high inter-assay variability in
excess of the acceptance criteria of less than 30%, albeit
the intra-assay variability was less than 11.5% across all
three experiments.
Generally, interpolation increased the variability in the
ratios between the “normal” and “simulated diseased”
panels, with CVs of 5.91 - 70.76%, compared with the
CV range of 0.19 - 10.78% associated with the ratios
between the two panels derived from the mean signal
output data. Hence the material may be used to evaluate
the robustness the platform by evaluating the perfor-
mance of these assays in terms of the signal output,
rather than by interpolation from the internal standard
curves.
Implementation of the QC spike protein in a model
system
The QC material was spiked into six single donor ovar-
ian cancer plasma samples (termed as OC samples) and
six single donor normal plasma samples. Three separate
experiments were performed to evaluate the reproduci-
bility of detecting the six spiked analytes, in addition to
three putative ovarian cancer biomarkers, IL-8, EGFR,
and osteopontin, alongside the FDA-approved marker
CA-125. If all four candidate biomarkers are appropriate
markers for ovarian cancer, differential expression of
these cancer markers is anticipated between the normal
and OC samples. It is anticipated that the spiked pro-
teins are detectable at the same abundance if all samples
are supplemented with the same quantity of QC
material.
The QC material when spiked into the plasma sam-
ples could serve as a useful indicator to verify the
robustness of the platform if the signal outputs for its
component proteins are reproducible between experi-
mental runs and independent of matrix effects. From
the plots of the signal outputs, it was apparent that
three proteins, caronte, soggy and lysozyme, fulfilled this
criteria (Figure 2). A linear mixed effects model fit by
Pang et al. BMC Research Notes 2011, 4:281
http://www.biomedcentral.com/1756-0500/4/281
Page 4 of 10A
B
CF
E
D
Figure 1 Evaluation of cross-reactivity associated with the panel of protein standards. Uniplexed assays for each analyte: (A) CCL6, (B)
lungkine, (C) caronte, (D) soggy, (E) luciferase and (F) lysozyme were performed, incorporating the omission of a single protein from the
complete mixture of six protein QC material, to evaluate the contribution of each analyte to the overall mean signal output. The data points
denote the mean values for each experiment, for day 1 (blue rhombuses), day 2 (pink squares) and day 3 (green triangles), and the error bars
represent the SD from triplicate determinants.
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formed using all data from three separate experiments
and the fixed effects are a measure of the statistical dif-
ference between the control and diseased plasma sam-
ples, based on the signal output observed. The p-values
for lysozyme and soggy were 0.175 and 0.189 respec-
tively, which suggests there is no significant difference
between the control and cancer plasma samples, across
three separate experiments. The p-value for the caronte
data was 0.056, which may be indicative of borderline
statistical difference between the two sample groups.
Sample matrix effects were more apparent for the detec-
tion of CCL6, lungkine and luciferase (Figure 2). This
led to variable signal outputs across the twelve single
donor samples for CCL6, lungkine and luciferase (Fig-
ures 2A, B and 2E). With these three spike proteins,
there were generally lower signal outputs among the
normal samples (donors 1-6) compared with the OC
samples (donors 7-12), with the following exceptions:
elevated signals for donor 2 and lower signal outputs for
donors 10 and 12. However, only the intra-assay and
inter-assay CVs of the caronte, soggy, lysozyme, and
lungkine assays were typically less than the QC accep-
tance criteria of 30% variability (Additional file 5).
Although the intra-assay variability for luciferase was
typically less than 30%, the inter-assay variability was
marginally higher than the acceptance criteria. However
higher inter-assay variability has been documented for
other commercial MSD assays in the context of cytokine
assessments (e.g. Chowdhury et al., 2009 [12]), in spite
of low intra-assay variability. Both the intra- and inter-
assay variability of the CCL6 assay were greater than
30%, which suggests that the assay was not sufficiently
robust when using the individual plasma donor samples.
Of the four candidate biomarkers, the major contribu-
tor to the separation of the data for the two patient
populations was IL-8 (data not shown). In addition to
evaluating the IL-8 data in terms of the mean signal
outputs (Figure 3A) for each experiment, interpolated
concentrations of IL-8 detected within the twelve single
donor plasma samples were also shown (Figure 3B).
Interpolation of data from internal standard curves is a
commonly adopted normalisation approach for immu-
noassays to assign relative concentrations of the analytes
of interest within the test samples. Although both meth-
ods of analysis indicated some separation between the
normal and diseased datasets, it was clear that interpo-
lated IL-8 concentration increased variability observed
between experiments with the normal plasma samples.
The intra-assay and inter-assay variability for CA-125
and EGFR were generally less than the acceptance cri-
teria of 30% variability (Additional file 5). Anomalous
results with the third IL-8 dataset may have contributed
to the inter-assay CV of greater than 30%. The osteo-
pontin assays of the individual donor plasma samples
were not sufficiently robust as evidenced by the high
intra- and inter-assay CVs of more than 30% variability
(Additional file 5).
Discussion
To demonstrate platform robustness, the signal output
of the component proteins should not exhibit significant
statistical difference between the individual donor
plasma samples, or between technical replicates and
separate experimental runs. The component proteins
exhibiting differential signals between distinct samples
would be indicative of the existence of matrix effects
that may also influence credibility in the data derived
for the detection of the target analytes. In this pilot
study, the purpose of the generic QC material was illu-
strated by immunoassay using a single set of antibodies.
These data form a preliminary finding, and all aspects of
variability inducing parameters should be subjected to a
full validation. A larger scale study with a greater num-
ber of individual donor plasma samples, platforms and
antibodies may be required to determine the true cri-
teria for acceptable variability in the signal outputs for
the component proteins. Generic protein standards have
Table 2 Detection of compositional fold-changes in selected analytes between two panels of spike proteins
Analyte Ratio of signal outputs from the “normal” to “simulated
diseased” panels of protein standards (n = 3)
Ratio of interpolated concentrations from the “normal” to
“simulated diseased” panels of protein standards (n = 3)
Expected Actual Expected Actual
CCL6 1:2 1: 1.26 ± 0.06 1:2 1: 1.72 ± 0.28
Lungkine 1:1 1: 0.94 ± 0.05 1:1 1: 1.71 ± 1.21
Caronte 1:1 1: 1.11 ± 0.21 1:1 1: 1.20 ± 0.29
Soggy 3:1 3: 1.02 ± 0.11 3:1 3: 0.96 ± 0.11
Luciferase 3:2 3: 1.80 ± 0.19 3:2 3: 1.86 ± 0.43
Lysozyme 1:1 1: 0.96 ± 0.06 1:1 1: 0.88 ± 0.32
The ratios of each analyte between the “simulated normal and diseased” panels of proteins are tabulated below, in terms of signal outputs and interpolated
concentrations. Theoretical ratios were calculated based on all analyte concentrations correlating with the linear working range of the assay. Theoretically within
the “simulated diseased” panel, the concentration of CCL6 was 2-fold higher, whereas the concentrations of soggy and luciferase were 3-fold and 1.5-fold lower,
respectively, compared with the same analytes within the “normal” generic panel of protein standards
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ods, however, it is anticipated that this QC material may
be applied to all protein-based detection methods,
including mass spectrometry and other immunoassays.
One limitation with immunoassays is the potential for
cross-reactivity between proteins and non-cognate
antibodies that may impair the detection of the target
analyte. We have shown that each protein was detect-
able amidst the presence of the five non-cognate target
proteins. However, with the ovarian cancer pilot study
involving single donor plasma samples, the CCL6, lung-
kine and luciferase assays exhibited differential degrees
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Figure 2 Evaluation of the utility of each spike protein in single donor plasma samples. The mean signal output of (A) CCL6, (B) lungkine,
(C) caronte, (D) soggy, (E) luciferase and (F) lysozyme from twelve single donor plasma samples supplemented to comprise the 1× stock of the
QC material were determined from three separate experiments with n = 3. The data points denote the mean values for experiment 1 (blue
rhombuses), experiment 2 (pink squares) and experiment 3 (green triangles), and the error bars represent the SD.
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Page 7 of 10of cross reactivity, giving rise to the variable signal out-
puts observed when the QC material was spiked in dif-
ferent patient samples. Interestingly, there was
concordance among these three assays in terms of their
signal profiles across the twelve donor samples, in spite
of the concern regarding the robustness of the CCL6
assay. As this cross-reactivity was not due to the pre-
sence of the five other proteins within the spike panel
per se, it was most probable that the variable protein
composition of the biological matrix bound non-specifi-
cally to some of the antibodies within these assays.
Lungkine as well as CCL6 and luciferase, at their cur-
rent designated spike concentrations could not be used
as the QC material of platform reliability for immunoas-
says with single donor plasma samples, with the current
set of antibody pairs. However, this does not exclude
their use as spike materials using distinct antibody pairs
or for assays without antibodies (e.g. mass
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Figure 3 Evaluation of the reproducibility of IL-8 detection. IL-8 detection of the twelve single donor plasma samples, are displayed as (A)
the mean signal output and as (B) interpolated concentrations of IL-8 from the internal standard curves. These data points (blue rhombuses) are
the mean values of triplicate experiments, incorporating triplicate replicate determinants. The error bars denote the SD of the three separate
experiments.
Pang et al. BMC Research Notes 2011, 4:281
http://www.biomedcentral.com/1756-0500/4/281
Page 8 of 10spectrometry), or as a spike material for other biological
samples. These alternative uses will require further
investigation on a case-specific basis. Nonetheless, with
the existing assay conditions for these three component
proteins, their signal outputs are valuable indicators of
matrix effects associated with individual samples. Identi-
f y i n gm a t r i xe f f e c t si so fi m p o r t a n c ea st h i sp h e n o m -
enon may also adversely affect the accuracy of
quantifying the presence of the target analyte.
Hence, this subset of proteins may collectively high-
light the need for caution when evaluating the level of
robustness for the test analyte data. Conversely, soggy,
lysozyme and possibly caronte do not exhibit sensitivity
to sample matrix effects. Hence these latter three pro-
t e i n sm a ys e r v ea si n d i c a t o r so ft h er o b u s t n e s so ft h e
platform.
Another limitation of many antibody-based assays is
the narrow linear range of the working assays, especially
when calibrants are spiked into a biological matrix (e.g.
plasma) rather than a buffer. Assays may not always
exhibit a sufficiently broad linear range encompassing
the full concentration coverage for physiological status,
leading to interpolation of some data from a non-linear
portion of the fitted curve. Albeit curve-fitting within an
experiment may be robust, calibration curves may be
susceptible to changes in the trendline thus increasing
variability between distinct experiments. This subse-
quently reduces the capacity for robust inter-experiment
comparison. High variability with the interpolated ana-
lyte concentrations via internal calibration curves from
different experimental runs is observed when evaluating
the the normal and “simulated disease” protein panels,
as well as for IL-8 detection.
In this instance, IL-8 concentration in the OC samples
coincided with the linear portion of the IL-8 standard
curve, whereas the concentrations of IL-8 associated
with normal plasma fell outside this robust range. This
brings into question the need for a standard curve,
given that detection above an assigned cut-off threshold
(e.g. the mean of the normal IL-8 plasma concentration
± 3 SD) may suffice for the diagnosis of disease. The
incorporation of internal standard curves also utilises
numerous additional wells to ensure there are sufficient
datapoints for robust curve fitting, with adequate techni-
cal replication. However, using the QC material in lieu
of internal calibrants for each analyte may demonstrate
the platform is fit-for-purpose and improve on assay
throughput by reducing the number of wells consumed
by calibrants.
Conclusions
We have shown the utility of the generic protein QC
material as an indicator of platform performance and
matrix effects, using immunoassays on the MSD
Sector 6000 Imager platform. The QC material may
also be used alone to evaluate bias introduced by vari-
able instruments, operators or reagents. This panel of
proteins has also exhibited suitable homogeneity and
stability for this application. The material can be
incorporated into a “quality metrics” toolkit for asses-
sing protein biomarker platform performance, addres-
sing issues associated with insufficient assay
robustness delineated in the FDA’s Critical Path Initia-
tive in 2004.
Additional material
Additional file 1: Homogeneity of the QC material. Ten tubes of the
10× stock QC material were selected randomly from the stock of
material stored at -20°C, and three separate dilution steps were
performed per tube to evaluate the reproducibility of separate dilution
steps. Nested ANOVA was performed to evaluate the variability between
distinct tubes and the dilution steps (combined with the variability of the
different tubes), as well as the overall variability of the platform.
Additional file 2: Evaluation of the short term stability of the 10×
stock QC material. The isochronous assay for each of the six protein
components of the QC material was performed, following exposure of
the 10× stock to room temperature, for 1 h, 1 day, 3 days and 7 days
prior to the assays.
Additional file 3: Evaluation of the long term stability of the 10×
stock QC material. Uniplexed assays were performed for each the six
protein components of the diluted 1× QC material at monthly intervals,
following storage of the 10× stock QC material in the -20°C freezer, -80°C
freezer, or as a lyophilised powder stored at -20°C.
Additional file 4: Standard error estimated associated to each ratio
of normal and simulated diseased signal output for each analyte.
The formula used to calculate the uncertainty associated with the
derivation of the ratios between the normal and simulated diseased
panels for each analyte is shown.
Additional file 5: Tabulated variability of the assays. Intra- and inter-
assay variability for the 6 spike proteins and 4 candidate ovarian cancer
biomarkers derived from three separate experiments conducted to
evaluate the implementation of the QC spike protein in a model system.
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